Versatile tests for window mean survival time

被引:3
作者
Paukner, Mitchell [1 ]
Chappell, Richard [1 ,2 ]
机构
[1] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA
[2] Univ Wisconsin, Biostat & Med Informat, Madison, WI USA
关键词
logrank test; nonproportional hazards; survival data; weighted rank test; TRIAL; CHEMOTHERAPY; DIFFERENCE; DOCETAXEL;
D O I
10.1002/sim.9444
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Window mean survival time (WMST) evaluates the mean survival between a lower time horizon, tau 0$$ {\tau}_0 $$, and an upper time horizon, tau 1$$ {\tau}_1 $$. As a flexible extension of restricted mean survival time, specific clinically relevant windows of time can be assessed for survival difference accompanied by a communicable interpretation of estimates and tests. In its original application, WMST required the pre-specification of a window through the selection of appropriate window bounds, tau 0$$ {\tau}_0 $$ and tau 1$$ {\tau}_1 $$. In the instance of severe window misspecification of tau 0$$ {\tau}_0 $$ and tau 1$$ {\tau}_1 $$, the analysis may suffer from low power and a less meaningful interpretation. In this article, we introduce versatile tests whose procedures are based on the simultaneous use of multiple WMST test statistics that are asymptotically normal under the null hypothesis of no difference between two groups. Simulations are performed to examine the power of the tests in moderate sample sizes when the data are uncensored to heavily censored with a ramp-up enrollment period. The survival scenarios chosen for simulation are intended to imitate those which are commonly encountered in oncology, especially in trials involving immunotherapies. Implementation of the procedures is discussed in two real data examples for illustration. Functions for performing versatile WMST tests are provided in the survWMST package in R.
引用
收藏
页码:3720 / 3736
页数:17
相关论文
共 35 条
  • [1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [2] Statistical issues and challenges in immuno-oncology
    Chen, Tai-Tsang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2013, 1
  • [3] Comparison of survival distributions in clinical trials: A practical guidance
    Chen, Xiaotian
    Wang, Xin
    Chen, Kun
    Zheng, Yeya
    Chappell, Richard J.
    Dey, Jyotirmoy
    [J]. CLINICAL TRIALS, 2020, 17 (05) : 507 - 521
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] Do immune checkpoint inhibitors need new studies methodology?
    Ferrara, Roberto
    Pilotto, Sara
    Caccese, Mario
    Grizzi, Giulia
    Sperduti, Isabella
    Giannarelli, Diana
    Milella, Michele
    Besse, Benjamin
    Tortora, Giampaolo
    Bria, Emilio
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S1564 - S1580
  • [6] Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
    Freidlin, Boris
    Korn, Edward L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (35) : 3455 - +
  • [7] A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES
    GEHAN, EA
    [J]. BIOMETRIKA, 1965, 52 : 203 - +
  • [8] Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
    Guyot, Patricia
    Ades, A. E.
    Ouwens, Mario J. N. M.
    Welton, Nicky J.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
  • [9] A CLASS OF RANK TEST PROCEDURES FOR CENSORED SURVIVAL-DATA
    HARRINGTON, DP
    FLEMING, TR
    [J]. BIOMETRIKA, 1982, 69 (03) : 553 - 566
  • [10] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
    Hodi, F. Stephen
    O'Day, Steven J.
    McDermott, David F.
    Weber, Robert W.
    Sosman, Jeffrey A.
    Haanen, John B.
    Gonzalez, Rene
    Robert, Caroline
    Schadendorf, Dirk
    Hassel, Jessica C.
    Akerley, Wallace
    van den Eertwegh, Alfons J. M.
    Lutzky, Jose
    Lorigan, Paul
    Vaubel, Julia M.
    Linette, Gerald P.
    Hogg, David
    Ottensmeier, Christian H.
    Lebbe, Celeste
    Peschel, Christian
    Quirt, Ian
    Clark, Joseph I.
    Wolchok, Jedd D.
    Weber, Jeffrey S.
    Tian, Jason
    Yellin, Michael J.
    Nichol, Geoffrey M.
    Hoos, Axel
    Urba, Walter J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) : 711 - 723